Protein / target
Receptor tyrosine-protein kinase erbB-3
Protein at a glance
Biological role
Protein tyrosine kinase activator activity
Primary system
Nervous system
Strongest disease association
visceral neuropathy, familial, 1, autosomal recessive
Therapeutic maturity
Clinically validated target
Druggability
Small molecule
Clinical development
3 approved · 14 in clinical development
Derived from structured UniProt, Open Targets and literature data on this page.
Protein profile
Canonical identity and biological annotation from UniProt.
Function
Tyrosine-protein kinase that plays an essential role as cell surface receptor for neuregulins. Binds to neuregulin-1 (NRG1) and is activated by it; ligand-binding increases phosphorylation on tyrosine residues and promotes its association with the p85 subunit of phosphatidylinositol 3-kinase (PubMed:20682778). May also be activated by CSPG5 (PubMed:15358134). Involved in the regulation of myeloid cell differentiation (PubMed:27416908)
Subcellular location
Domains and Gene Ontology detail (47)Hide
Domains & features
Gene Ontology
- Capical plasma membrane
- Cbasal plasma membrane
- Cbasolateral plasma membrane
- CERBB3:ERBB2 complex
- Cextracellular space
- Clateral plasma membrane
- Cplasma membrane
- Cpostsynaptic membrane
- Creceptor complex
- FATP binding
- FErbB-3 class receptor binding
- Fgrowth factor binding
Biological roles
What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.
View supporting evidenceHide supporting evidence
Kinase signalling
- ·Tyrosine-protein kinase that plays an essential role as cell surface receptor for neureg…
- ·protein kinase activity
- ·phosphatidylinositol 3-kinase/protein kinase B signal transduction
- ·positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction
Apoptosis & cell death
- ·negative regulation of apoptotic process
- ·negative regulation of neuron apoptotic process
- ·neuron apoptotic process
Synaptic signalling
- ·postsynaptic membrane
Cell adhesion
- ·negative regulation of cell adhesion
View underlying pathways (15)Hide underlying pathways
Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.
Interaction neighbourhood
Proteins with the strongest functional or physical association. Node size and line weight reflect STRING confidence; hover or select a partner to inspect one association.
Functional and physical associations from STRING v12.0. Only associations with this protein are drawn — partner-to-partner links are not part of this evidence.
Drugs targeting this protein
Whether each drug engages this protein directly or through a complex, and how many other targets are recorded for it. Direct binders with few recorded targets are listed first.
Receptor tyrosine-protein kinase erbB-3 binding agent
Appears in clinical studies involving neoplasm, non-small cell lung carcinoma, breast cancer, colorectal cancer
ErbB-2/ErbB-3 heterodimer inhibitor
Appears in clinical studies involving non-small cell lung carcinoma, pancreatic neoplasm, breast cancer, malignant pancreatic neoplasm
ChEMBL mechanism, action type and target identity. Open Targets clinical status and indications.
Translational evidence
Why this target matters therapeutically — disease associations, drugs in development, tractability and safety, from Open Targets.
Strongest genetic associations
Human genetic evidence — the most direct causal link between this target and a disease.
Highest-confidence therapeutic associations
Diseases where a drug acting on this target has already reached clinical development.
Highest overall evidence
Remaining associations by Open Targets' aggregated evidence score.
Show all associationsHide all associations
Open Targets ranks 2,062 associations for this target and we store the top 10 by aggregated score. The long tail is largely literature co-mention and RNA-expression evidence, not evidence that this target drives those diseases.
Known drugs · 17 total
neoplasm · non-small cell lung carcinoma · breast cancer
neoplasm
colorectal cancer · head and neck squamous cell carcinoma · head and neck squamous cell carcinoma
thyroid gland carcinoma · medullary thyroid gland carcinoma · medullary thyroid gland carcinoma
non-small cell lung carcinoma · pancreatic neoplasm · breast cancer
non-small cell lung carcinoma · HER2 positive breast carcinoma · non-small cell lung carcinoma
colorectal cancer · head and neck cancer · non-small cell lung carcinoma
breast cancer · gastric adenocarcinoma · gastric carcinoma
non-small cell lung carcinoma · breast cancer
Tractability
Clinical trials
Trials of drugs that target this protein — reached indirectly through those drugs, so a trial listed here studies the drug, not the protein.
Show remaining trials (18)Hide
ClinicalTrials.gov via the drug-target graph.
Forefront confidence
Our own weighting of the evidence behind each disease association. Human genetics and clinical evidence count for most; literature co-mention counts for little, because two entities sharing an abstract is not evidence that one drives the other.
The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the underlying per-type scores are shown above so the calculation can be checked.
What's happening now
Recent activity around this target, drawn from one canonical event stream. Every item is reached through 2 drugs that target this protein, so each event is news about that drug rather than about the protein directly.
- New publicationPatritumab deruxtecan in leptomeningeal metastatic disease of solid tumors: the phase 2 TUXEDO-3 trial.
- New publicationEfficacy of Zenocutuzumab in <i>NRG1</i> Fusion-Positive Cancer.
- New publicationPatritumab Deruxtecan (HER3-DXd), a Human Epidermal Growth Factor Receptor 3-Directed Antibody-Drug Conjugate, in Patients With Previously Treated Human Epidermal Growth Factor Receptor 3-Expressing Metastatic Breast Cancer: A Multicenter, Phase I/II Trial.
- New publicationHERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy.
Objective event titles are shown unmodified; the event kind and significance line are derived from structured fields. Forefront AttentionEvent stream aggregating Europe PMC Regulatory filings ClinicalTrials.gov.